GlassScriptPhysician profile
Joseph P Calderone
NPI 1003841479
$5,377.62
in general payments reported to CMS, 2019-2025
29 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $195 · 2021: $742 · 2022: $1,048 · 2023: $807 · 2024: $664 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.13 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $707.55 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Bausch & Lomb Americas INC. | $618.02 | 2022-2025 | Miebo, Xiidra, Lotemax Sm |
| Glaukos Corporation | $538.19 | 2019-2025 | Idosetr |
| Allergan, INC. | $450.06 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $387.50 | 2020-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $330.50 | 2019-2021 | |
| Abbvie INC. | $255.09 | 2022-2025 | Durysta, Lumigan, Vuity |
| Sun Pharmaceutical Industries INC. | $234.95 | 2019-2025 | Cequa |
| Dompe US, INC. | $230.61 | 2022-2025 | Oxervate |
| Sight Sciences, INC. | $211.93 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $166.54 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $162.72 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $147.75 | 2020-2022 | |
| New World Medical,INC. | $133.72 | 2022 | |
| Alcon Vision LLC | $131.16 | 2019-2025 | Eysuvis, Simbrinza, Tryptyr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $130.49 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Oyster Point Pharma, INC. | $118.18 | 2022-2025 | Tyrvaya |
| Eyepoint US, INC. | $115.67 | 2019-2021 | |
| Ekos Corporation | $53.34 | 2019 | |
| Eyevance Pharmaceuticals LLC | $40.24 | 2019 | |
| Harrow Eye, LLC | $36.00 | 2025 | Vevye |
| Rayner Intraocular Lenses Limited | $34.75 | 2022-2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Ocular Therapeutix, INC. | $30.38 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $29.25 | 2020-2021 | |
| Biotissue Holdings INC. | $24.23 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $15.00 | 2025 | |
| Shire North American Group INC | $14.84 | 2019 | |
| Horizon Therapeutics Plc | $14.72 | 2022 | |
| Omeros Corporation | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Calderone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.